Investor directory

Euphrates Vascular

Euphrates Vascular specializes in the development of medical devices aimed at treating vascular occlusions associated with vascular diseases. The company has created a Magnetically-Enhanced Diffusion system that utilizes patented magnet-based technology to enhance the delivery of iron-oxide MED MicroBeads and clot-busting medications. This innovative approach allows for a significantly faster transport of these treatments compared to traditional methods, thereby enabling healthcare providers to improve patient outcomes in conditions such as stroke. Euphrates Vascular was formed through the merger of Pulse Therapeutics and ICHOR Vascular, positioning it as a leader in advancing vascular treatment solutions.

Top Stages

Acquisition
http://euphratesvascular.com
https://crunchbase.com/organization/euphrates-vascular
https://facebook.com/pulsemedsystem
https://linkedin.com/company/euphrates-vascular
https://pitchbook.com/profiles/company/50839-21
https://twitter.com/pulsemedsystem

Martin Akhavan

CEO and Chairman

Catherine Matthes

CFO

1 past transactions

Euphrates Vascular

Acquisition in 2019
As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.